Physician profile
Andrew Harb
NPI 1720641798
$6,952.08
in general payments reported to CMS, 2019-2025
18 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $114 · 2021: $158 · 2022: $3,437 · 2023: $1,354 · 2024: $880 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914 · Travel and Lodging: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.30 |
| Travel and Lodging | $1,328.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,878.15 | 2021-2022 | |
| Abbvie INC. | $1,552.97 | 2022-2025 | |
| Boston Scientific Corporation | $1,223.58 | 2021-2025 | Wavewriter Alpha Prime 16, Accolade Sr |
| Nevro Corp. | $717.11 | 2023-2024 | Senza |
| Arthrex, INC. | $482.45 | 2025 | |
| Medtronic, INC. | $239.08 | 2022-2023 | Synchromedii |
| Coloplast Corp | $128.14 | 2024 | |
| Averitas Pharma INC. | $125.75 | 2024 | Qutenza |
| Si-Bone, INC. | $125.53 | 2023 | |
| Genzyme Corporation | $114.24 | 2020 | |
| Biotronik Nro, INC. | $97.86 | 2025 | Prospera |
| Stryker Corporation | $78.60 | 2025 | Pangea, Optablate |
| Ardelyx, INC. | $70.44 | 2025 | Ibsrela |
| Pacira Pharmaceuticals Incorporated | $40.22 | 2025 | Iovera, Zilretta |
| Pfizer INC. | $26.49 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $17.66 | 2025 | Hymovis |
| Spr Therapeutics, INC | $17.32 | 2025 | Sprint Pns System |
| Janssen Biotech, INC. | $16.49 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Harb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.